| Dr Mark A Thimineur, MD | |
|
130 Division St, 1st Floor, Derby, CT 06418 | |
| (203) 732-1570 | |
| (203) 732-1576 |
| Full Name | Dr Mark A Thimineur |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 35 Years |
| Location | 130 Division St, Derby, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336180314 | NPI | - | NPPES |
| 3149086006 | Other | CT | CIGNA |
| 001331321 | Medicaid | CT | |
| 4569760 | Other | CT | AETNA |
| HEALTH CONNECTICUT P | Other | CT | 223514271 |
| 223514271 | Other | CT | HMC/PPO |
| 223514271 | Other | CT | MASHANTUCKET |
| 0V0370 | Other | CT | HEALTHNET |
| 010033132CT02 | Other | CT | BLUE CROSS BLUE SHIELD |
| 223514271 | Other | CT | UNITED HEALTHCARE |
| 223514271 | Other | CT | CHN |
| 764977 | Other | CT | CONNECTICARE |
| 00133132101 | Other | CT | BLUECARE FAMILY PLAN |
| A752119 | Other | CT | OXFORD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | 033132 (Connecticut) | Primary |
| 207L00000X | Anesthesiology | 033132 (Connecticut) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Midstate Medical Center | Meriden, CT | Hospital |
| Griffin Hospital | Derby, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Comprehensive Pain And Headache Treatment Centers Llc | 2860465796 | 6 |
News Archive
The Ontario government should fund the $6 million deficit of the North Bay General Hospital, Ontario Council of Hospital Unions/CUPE requested today. OCHU represents 25,000 nurses, tradespersons, clerical, housekeeping, dietary and support and service staff at 65 Ontario hospitals, including employees represented by CUPE Local 139 at the North Bay General Hospital.
Results from two early clinical studies show the first version of an oral PCSK9-inhibitor cholesterol-lowering medicine was well tolerated and highly effective at reducing high levels of LDL cholesterol, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2021.
FemmePharma Global Healthcare, a privately held women's health company dedicated to improving the quality of life for women, today announces completion of its Phase II clinical dose ranging/safety trial with FP 1097 in women suffering from urinary incontinence or overactive bladder.
Leica Microsystems signed a 14-month supply contract with NKT Photonics to deliver significant numbers of its market-leading SuperK EXTREME supercontinuum lasers.
BioSante Pharmaceuticals, Inc. today announced the initiation of a LibiGel (testosterone gel) clinical trial to evaluate its effect on cognitive function in menopausal women. The trial is a randomized, 6-month comparison of the effect of LibiGel compared to placebo treatment on a variety of learning and memory tasks. The study is being conducted by Dr. Susan Davis, Professor of Women's Health, Department of Medicine, Monash University Women's Health Program in Australia.
› Verified 7 days ago
| Entity Name | Comprehensive Pain And Headache Treatment Centers Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467672592 PECOS PAC ID: 2860465796 Enrollment ID: O20040818000301 |
News Archive
The Ontario government should fund the $6 million deficit of the North Bay General Hospital, Ontario Council of Hospital Unions/CUPE requested today. OCHU represents 25,000 nurses, tradespersons, clerical, housekeeping, dietary and support and service staff at 65 Ontario hospitals, including employees represented by CUPE Local 139 at the North Bay General Hospital.
Results from two early clinical studies show the first version of an oral PCSK9-inhibitor cholesterol-lowering medicine was well tolerated and highly effective at reducing high levels of LDL cholesterol, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2021.
FemmePharma Global Healthcare, a privately held women's health company dedicated to improving the quality of life for women, today announces completion of its Phase II clinical dose ranging/safety trial with FP 1097 in women suffering from urinary incontinence or overactive bladder.
Leica Microsystems signed a 14-month supply contract with NKT Photonics to deliver significant numbers of its market-leading SuperK EXTREME supercontinuum lasers.
BioSante Pharmaceuticals, Inc. today announced the initiation of a LibiGel (testosterone gel) clinical trial to evaluate its effect on cognitive function in menopausal women. The trial is a randomized, 6-month comparison of the effect of LibiGel compared to placebo treatment on a variety of learning and memory tasks. The study is being conducted by Dr. Susan Davis, Professor of Women's Health, Department of Medicine, Monash University Women's Health Program in Australia.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark A Thimineur, MD 130 Division St, 1st Floor, Derby, CT 06418 Ph: (203) 732-1570 | Dr Mark A Thimineur, MD 130 Division St, 1st Floor, Derby, CT 06418 Ph: (203) 732-1570 |
News Archive
The Ontario government should fund the $6 million deficit of the North Bay General Hospital, Ontario Council of Hospital Unions/CUPE requested today. OCHU represents 25,000 nurses, tradespersons, clerical, housekeeping, dietary and support and service staff at 65 Ontario hospitals, including employees represented by CUPE Local 139 at the North Bay General Hospital.
Results from two early clinical studies show the first version of an oral PCSK9-inhibitor cholesterol-lowering medicine was well tolerated and highly effective at reducing high levels of LDL cholesterol, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2021.
FemmePharma Global Healthcare, a privately held women's health company dedicated to improving the quality of life for women, today announces completion of its Phase II clinical dose ranging/safety trial with FP 1097 in women suffering from urinary incontinence or overactive bladder.
Leica Microsystems signed a 14-month supply contract with NKT Photonics to deliver significant numbers of its market-leading SuperK EXTREME supercontinuum lasers.
BioSante Pharmaceuticals, Inc. today announced the initiation of a LibiGel (testosterone gel) clinical trial to evaluate its effect on cognitive function in menopausal women. The trial is a randomized, 6-month comparison of the effect of LibiGel compared to placebo treatment on a variety of learning and memory tasks. The study is being conducted by Dr. Susan Davis, Professor of Women's Health, Department of Medicine, Monash University Women's Health Program in Australia.
› Verified 7 days ago